Cota CMO, Experts to Examine Strong Data's Role in Precision Medicine

When key opinion leaders discuss companies at the forefront of healthcare technology, they often mention Cota. The New York City-based real-world data and analytics company has forged partnerships with plenty of blue-chip oncology institutions, from Memorial Sloan Kettering Cancer Center to Hackensack Meridian Health, leveraging its high-end technologies to make sense of unstructured data and improve care.

Now, Cota’s chief medical officer, Andrew Norden, MD, is slated to discuss whether precision medicine requires precise data alongside a handful of leaders in the field. The panel is scheduled for Thursday, Feb. 8, during the HealthXL Global Gathering, at the National Robotics Engineering Center in Pittsburgh, Pennsylvania.

But the panel discussion won’t see the experts simply grapple with a pressing issue. Indeed, Norden is expected to describe how “Cota is accelerating the path to precision medicine and oncology value-based care with providers across the country,” according to the company. What does that mean? Norden is going to lay out how Cota’s work for providers like Hackensack Meridian Health and Baptist Health South Florida has been progressing.

The event essentially offers a chance to better understand the inner workings of one of the leading healthcare analytics start-ups.

Cota used real-world evidence analytics, decision support, and value-based tracking to provide solutions for its clients. Its Cota Notal Address precision patient classification system and Cota Real-World Evidence collection of oncology patient data help “improve quality and outcome in cancer care, increase oncology margins in fee-for-service and value-based arrangements and assist practices looking to transition to value-based care,” according to the organization.

According to a number of Healthcare Analytics News™ interviews with Cota executives, the technologies enable hospitals to monitor patients and physicians, to see which care paths are most successful and where value, in both outcomes and money, can be increased.

Joining Norden on the HealthXL panel are Adrian Lee, PhD, director of the Institute for Precision Medicine at University of Pittsburgh; Alan Russell, PhD, highmark distinguished career professor at Carnegie Mellon University; and Lisa Alderson, MBA, co-founder and CEO of Genome Medical.

The HealthXL Global Gathering also features panels on big data and artificial intelligence, patient empowerment and data ownership, and how cities of the future might foster wellness.